John W Mccutcheon

US Patent:

7412977, Aug 19, 2008

Filed:

Mar 6, 2003

Appl. No.:

10/384899

Inventors:

Antony J. Fields - San Francisco CA, US
Ronald Hundertmark - San Mateo CA, US
John McCutcheon - Menlo Park CA, US

Assignee:

Emphasys Medical, Inc. - Redwood City CA

International Classification:

A61M 11/00

US Classification:

12820024, 12820716, 12820524

Abstract:

Disclosed are methods and devices for regulating fluid flow in one or more lung regions that are supplied fluid through one or more collateral pathways. An identified region of the lung is targeted for volume reduction or collapse. The targeted lung region is then bronchially isolated to inhibit air from flowing into the targeted lung region through bronchial pathways that directly feed air to the targeted lung region. If the targeted lung region does not collapse after bronchially isolating the targeted lung region, then it is possible that a collateral pathway is feeding air to the targeted lung region, thereby preventing the targeted lung region from collapsing. In such a case, the collateral pathway is identified and air flow into the targeted lung region via the collateral pathway is reduced or eliminated.

US Patent:

7717115, May 18, 2010

Filed:

Nov 25, 2003

Appl. No.:

10/723273

Inventors:

Michael Barrett - Campbell CA, US
David Tholfsen - San Leandro CA, US
Michael Hendricksen - Redwood City CA, US
Ronald Hundertmark - San Diego CA, US
John McCutcheon - Menlo Park CA, US
Antony J. Fields - San Francisco CA, US
Jeffery J. Dolin - Belmont CA, US
Robert M. George - San Jose CA, US

Assignee:

Pulmonx Corporation - Redwood City CA

International Classification:

A61M 16/00
A62B 9/06

US Classification:

12820714, 12820715, 12820716, 12820026, 604158, 604159, 604160, 604161, 604162, 604163, 604192, 606191, 606192, 606193, 606194, 606198, 623 111

Abstract:

Disclosed is an apparatus for deploying a bronchial isolation device in a bronchial passageway in a lung of a patient. In one embodiment, the apparatus includes an outer shaft having a distal end. A housing is coupled to the distal end of the outer shaft and configured to receive the bronchial device. An inner shaft is slidably disposed within the outer shaft. A handle is adapted to move the outer shaft relative to both the inner shaft and the handle while the inner shaft remains fixed relative to the handle so as to eject the bronchial isolation device from the housing.

US Patent:

8465505, Jun 18, 2013

Filed:

May 2, 2012

Appl. No.:

13/462773

Inventors:

Michael Murillo - Menlo Park CA, US
Chris P. Bender - Oakland CA, US
Mark Y. Hirotsuka - San Jose CA, US
Michael J. Hendricksen - Redwood City CA, US
Justin D. Saliman - Los Angeles CA, US
John G. McCutcheon - Menlo Park CA, US

Assignee:

Ceterix Orthopaedics, Inc. - Menlo Park CA

International Classification:

A61B 17/04
A61B 17/10

US Classification:

606144, 606139, 606145

Abstract:

Devices, systems and methods for passing a suture. In general, described herein are suturing devices, such as suture passers, as well as methods of suturing tissue. These suture passing devices may include dual deployment suture passers in which a first distal jaw member is movable at an angle with respect to the longitudinal axis of the elongate body of the device and the second distal jaw member is retractable proximally to the distal end region of the elongate body and/or the first jaw member. Also described herein are suture passers in which the tissue penetrator passing the suture travels in an approximately sigmoidal pathway, with the distal end of the tissue penetrator extending distally from one jaw of the device.

US Patent:

8206684, Jun 26, 2012

Filed:

Feb 25, 2005

Appl. No.:

11/067025

Inventors:

John McCutcheon - Menlo Park CA, US
Antony J. Fields - San Francisco CA, US
David Peter Shaw - Christchurch, NZ

Assignee:

Pulmonx Corporation - Redwood City CA

International Classification:

A61N 33/44
A61M 11/00

US Classification:

424 125, 12820023

Abstract:

Disclosed is a method of regulating fluid flow for a targeted lung region. The method comprises injecting a therapeutic agent into the targeted lung region. The therapeutic agent induces a reaction in lung tissue of the targeted lung region or in a collateral pathway to the lung region to reduce collateral fluid flow into the targeted lung region. In one aspect, the method additionally comprises deploying a bronchial isolation device in the direct pathway to regulate fluid flow to the targeted lung region through the direct pathway. The therapeutic agent can comprise, for example, a sclerosing agent that induces a reaction that causes sclerosis in the lung tissue.

US Patent:

20030127090, Jul 10, 2003

Filed:

Nov 14, 2002

Appl. No.:

10/298387

Inventors:

Hanson Gifford - Woodside CA, US
John McCutcheon - Menlo Park CA, US
Antony Fields - San Francisco CA, US

Assignee:

Emphasys Medical, Inc.

International Classification:

A61F002/04

US Classification:

128/200240, 623/009000, 623/023650, 600/016000

Abstract:

Disclosed is a pump device that can be implanted into a body passageway, such as into a bronchial passageway. The pump device can be used to pump fluid through the body passageway, such as in order to assist the expiration of fluid from a region of the lung that fluidly communicates with the body passageway. The pump device includes a housing that defines an internal chamber, wherein fluid can flow through the chamber. The housing is dimensioned for insertion into a bronchial passageway. The pump device also includes a fluid propulsion mechanism in fluid communication with the chamber. The fluid propulsion mechanism is positioned to propel fluid through the chamber so as to pump fluid through the bronchial passageway in a desired direction.

US Patent:

20050016530, Jan 27, 2005

Filed:

Jul 8, 2004

Appl. No.:

10/887337

Inventors:

John McCutcheon - Menlo Park CA, US
Randy Campbell - Redwood City CA, US
Antony Fields - San Francisco CA, US

International Classification:

A62B007/00

US Classification:

128200240

Abstract:

Disclosed is a treatment planning method that can be used to maximize the effectiveness of minimally invasive treatment on a patient. Pursuant to the treatment planning method, the presence of lung disease, such as emphysema, is first identified, followed by a determination of the distribution and extent of damage of the disease, followed by a determination of whether the patient is suitable for treatment, and a determination of the appropriate strategy for treatment for a suitable patient.

US Patent:

20050178389, Aug 18, 2005

Filed:

Jan 26, 2005

Appl. No.:

11/044875

Inventors:

David Shaw - Christchurch, NZ
John McCutcheon - Menlo Park CA, US
Antony Fields - San Francisco CA, US

International Classification:

A61M011/00
A61M016/00

US Classification:

128207150

Abstract:

Disclosed are various disease indications and treatment methods that benefit from selective lung region isolation. A lung region is bronchially isolated by regulating the flow of fluid to and from the lung region, such as by implanting one or more bronchial isolation devices into one or more bronchial passageways that feed air to the lung region. The bronchial isolation devices can comprise, for example, one-way valves, two-way valves, occluders or blockers, ligating clips, glues, sealants, and sclerosing agents.

US Patent:

20060020347, Jan 26, 2006

Filed:

Mar 8, 2005

Appl. No.:

11/075633

Inventors:

Michael Barrett - Campbell CA, US
Michael Hendricksen - Redwood City CA, US
Alan Rapacki - Redwood City CA, US
Ronald Hundertmark - San Mateo CA, US
Jeffrey Dolin - Belmont CA, US
Robert George - San Jose CA, US
John McCutcheon - Menlo Park CA, US
Antony Fields - San Francisco CA, US

International Classification:

A61F 2/04

US Classification:

623023650

Abstract:

Disclosed are methods and devices for regulating fluid flow to and from a region of a patient's lung, such as to achieve a desired fluid flow dynamic to a lung region during respiration and/or to induce collapse in one or more lung regions. Pursuant to an exemplary procedure, an identified region of the lung is targeted for treatment. The targeted lung region is then bronchially isolated to regulate airflow into and/or out of the targeted lung region through one or more bronchial passageways that feed air to the targeted lung region.